Homocysteine and atherosclerosis
- PMID: 10554704
- DOI: 10.1097/00041433-199910000-00006
Homocysteine and atherosclerosis
Abstract
Elevated plasma total homocysteine is an independent risk factor for atherosclerotic vascular disease. Risk rises continuously across the spectrum of homocysteine concentrations and may become appreciable at levels greater than 10 mumol/l. A compelling case can be made for screening all individuals with atherosclerotic disease or at high risk. A reasonable, but unproven, goal for treatment is a plasma total homocysteine concentration less than 10 mumol/l. Folic acid is the mainstay of treatment, but vitamins B12 and B6 may have added benefit in selected patients. The results of ongoing randomized placebo-controlled trials will not be available for several years, but will help determine whether homocysteine lowering reduces the risk of cardiovascular disease.
Similar articles
-
Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group.Circulation. 1998 Feb 10;97(5):437-43. doi: 10.1161/01.cir.97.5.437. Circulation. 1998. PMID: 9490237
-
Folic acid and Vitamin B6 supplementation and plasma homocysteine concentrations in healthy young women.Int J Vitam Nutr Res. 1998;68(2):98-103. Int J Vitam Nutr Res. 1998. PMID: 9565824
-
Vitamins B6, B12, and folate: association with plasma total homocysteine and risk of coronary atherosclerosis.J Am Coll Nutr. 1998 Oct;17(5):435-41. doi: 10.1080/07315724.1998.10718790. J Am Coll Nutr. 1998. PMID: 9791839
-
Homocysteine. The association with atherosclerotic vascular disease in older persons.Geriatrics. 2003 Sep;58(9):22-4, 27-8. Geriatrics. 2003. PMID: 14518174 Review.
-
DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations.Clin Chem Lab Med. 2003 Nov;41(11):1392-403. doi: 10.1515/CCLM.2003.214. Clin Chem Lab Med. 2003. PMID: 14656016 Review.
Cited by
-
The Role of Fine Particles (PM 2.5) in the Genesis of Atherosclerosis and Myocardial Damage: Emphasis on Clinical and Epidemiological Data, and Pathophysiological Mechanisms.Cardiol Res. 2022 Oct;13(5):268-282. doi: 10.14740/cr1366. Epub 2022 Oct 25. Cardiol Res. 2022. PMID: 36405225 Free PMC article. Review.
-
Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.J Atheroscler Thromb. 2018 Sep 1;25(9):846-984. doi: 10.5551/jat.GL2017. Epub 2018 Aug 22. J Atheroscler Thromb. 2018. PMID: 30135334 Free PMC article. No abstract available.
-
Review of canine dilated cardiomyopathy in the wake of diet-associated concerns.J Anim Sci. 2020 Jun 1;98(6):skaa155. doi: 10.1093/jas/skaa155. J Anim Sci. 2020. PMID: 32542359 Free PMC article. Review.
-
Trait anger, hostility, serum homocysteine, and recurrent cardiac events after percutaneous coronary interventions.Am J Crit Care. 2009 Nov;18(6):554-61. doi: 10.4037/ajcc2009974. Am J Crit Care. 2009. PMID: 19880957 Free PMC article.
-
Pathogenesis and treatment of atherosclerosis in lupus.Rheum Dis Clin North Am. 2014 Aug;40(3):475-95, viii. doi: 10.1016/j.rdc.2014.04.003. Epub 2014 Jun 10. Rheum Dis Clin North Am. 2014. PMID: 25034157 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
